# Pliant Therapeutics Receives FDA Fast Track Designation for PLN-74809 for the Treatment of Primary Sclerosing Cholangitis

**URL:** <https://forum.livingwithpsc.org/t/pliant-therapeutics-receives-fda-fast-track-designation-for-pln-74809-for-the-treatment-of-primary-sclerosing-cholangitis/5055>\
**Category:** Life with Primary Sclerosing Cholangitis\
**Created:** [September 17, 2022, 5:05am UTC](https://forum.livingwithpsc.org/t/pliant-therapeutics-receives-fda-fast-track-designation-for-pln-74809-for-the-treatment-of-primary-sclerosing-cholangitis/5055 "2022-09-17T05:05:56Z")\
**Posts on this page:** 4\
**Page:** 1

<div class="post-metadata">

**Author:** ![GlasshalfFULL](https://avatars.discourse-cdn.com/v4/letter/g/45deac/32.png) [@GlasshalfFULL](https://forum.livingwithpsc.org/u/GlasshalfFULL)\
**Post date:** [September 17, 2022, 5:05am UTC](https://forum.livingwithpsc.org/t/pliant-therapeutics-receives-fda-fast-track-designation-for-pln-74809-for-the-treatment-of-primary-sclerosing-cholangitis/5055/1 "2022-09-17T05:05:56Z")

</div>

# Pliant Therapeutics Receives FDA Fast Track Designation for PLN-74809 for the Treatment of Primary Sclerosing Cholangitis

Havent seen anyone post about this yet so figured i would send the link out.

> **[Pliant Therapeutics Receives FDA Fast Track Designation for PLN-74809 for the...](https://www.globenewswire.com/en/news-release/2022/07/21/2483580/0/en/Pliant-Therapeutics-Receives-FDA-Fast-Track-Designation-for-PLN-74809-for-the-Treatment-of-Primary-Sclerosing-Cholangitis.html)**
>
> SOUTH SAN FRANCISCO, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics (NASDAQ: PLRX) announced today that PLN-74809, its oral,...

---

<div class="post-metadata">

**Author:** ![fcmmark](https://sea1.discourse-cdn.com/flex019/user_avatar/forum.livingwithpsc.org/fcmmark/32/2189_2.png) [@fcmmark](https://forum.livingwithpsc.org/u/fcmmark)\
**Post date:** [September 19, 2022, 12:27pm UTC](https://forum.livingwithpsc.org/t/pliant-therapeutics-receives-fda-fast-track-designation-for-pln-74809-for-the-treatment-of-primary-sclerosing-cholangitis/5055/2 "2022-09-19T12:27:25Z")

</div>

Thanks for sharing this article “GlasshalfFULL”. It does sound promising. We’ll keep looking out for what comes from the clinical trial studies.

Mark

---

<div class="post-metadata">

**Author:** ![jace0221](https://avatars.discourse-cdn.com/v4/letter/j/c68b51/32.png) [@jace0221](https://forum.livingwithpsc.org/u/jace0221)\
**Post date:** [September 19, 2022, 3:32pm UTC](https://forum.livingwithpsc.org/t/pliant-therapeutics-receives-fda-fast-track-designation-for-pln-74809-for-the-treatment-of-primary-sclerosing-cholangitis/5055/3 "2022-09-19T15:32:35Z")

</div>

Is there any information on the impact the drug has had in studies conducted so far? How do they define “treatment”?

---

<div class="post-metadata">

**Author:** ![JeffDC1](https://sea1.discourse-cdn.com/flex019/user_avatar/forum.livingwithpsc.org/jeffdc1/32/402_2.png) [@JeffDC1](https://forum.livingwithpsc.org/u/JeffDC1)\
**Post date:** [September 22, 2022, 12:28am UTC](https://forum.livingwithpsc.org/t/pliant-therapeutics-receives-fda-fast-track-designation-for-pln-74809-for-the-treatment-of-primary-sclerosing-cholangitis/5055/4 "2022-09-22T00:28:24Z")

</div>

There are a lot of people who hope that works well.